Related references
Note: Only part of the references are listed.Visual acuity and quality of life in dry eye disease: Proceedings of the OCEAN group meeting
Jose Benitez-del-Castillo et al.
OCULAR SURFACE (2017)
TFOS DEWS II Management and Therapy Report
Lyndon Jones et al.
OCULAR SURFACE (2017)
TFOS DEWS II Definition and Classification Report
Jennifer P. Craig et al.
OCULAR SURFACE (2017)
The role of systemic and topical fatty acids for dry eye treatment
Stefano Barabino et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2017)
Blood derived eye drops for the treatment of cornea and ocular surface diseases
Giuseppe Giannaccare et al.
TRANSFUSION AND APHERESIS SCIENCE (2017)
Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study
Jorge L. Alio et al.
OPHTHALMOLOGY AND THERAPY (2017)
Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
Morgan R. Godin et al.
CLINICAL OPHTHALMOLOGY (2017)
Enhanced Tearing by Electrical Stimulation of the Anterior Ethmoid Nerve
Mark Brinton et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2017)
Effects of Humidity on Tests of Tear Production
Fiona Buckmaster et al.
CORNEA (2016)
Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial
Andrea Leonardi et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2016)
Report of the Inaugural Meeting of the TFOS i2 = initiating innovation Series: Targeting the Unmet Need for Dry Eye Treatment
Wendy Chao et al.
OCULAR SURFACE (2016)
Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease
Jose Manuel Benitez-Del-Castillo et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2016)
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease Results of the Randomized Phase III OPUS-2 Study
Joseph Tauber et al.
OPHTHALMOLOGY (2015)
Safety and Efficacy of Lacrimal Drainage System Plugs for Dry Eye Syndrome A Report by the American Academy of Ophthalmology
Marcus M. Marcet et al.
OPHTHALMOLOGY (2015)
Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease Results of the OPUS-1 Phase 3 Study
John D. Sheppard et al.
OPHTHALMOLOGY (2014)
CALCIUM-PERMEABLE ION CHANNELS IN PAIN SIGNALING
Emmanuel Bourinet et al.
PHYSIOLOGICAL REVIEWS (2014)
Recent developments on dry eye disease treatment compounds
Basilio Colligris et al.
SAUDI JOURNAL OF OPHTHALMOLOGY (2014)
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Randomized, Multicenter Phase 3 Study Comparing 2% Rebamipide (OPC-12759) with 0.1% Sodium Hyaluronate in the Treatment of Dry Eye
Shigeru Kinoshita et al.
OPHTHALMOLOGY (2013)
Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye
Karen Meerovitch et al.
CLINICAL OPHTHALMOLOGY (2013)
A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients
Etsuko Takamura et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
TRPV1 Involvement in Inflammatory Tissue Fibrosis in Mice
Yuka Okada et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
High-Dose siRNAs Upregulate Mouse Eri-1 at both Transcription and Posttranscription Levels
Yingnan Bian et al.
PLOS ONE (2011)
TRPV1 Activation Is Required for Hypertonicity-Stimulated Inflammatory Cytokine Release in Human Corneal Epithelial Cells
Zan Pan et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents
C. A. Stein et al.
NUCLEIC ACIDS RESEARCH (2010)
The promises and pitfalls of RNA-interference-based therapeutics
Daniela Castanotto et al.
NATURE (2009)
RNAi therapeutics: a potential new class of pharmaceutical drugs
David Bumcrot et al.
NATURE CHEMICAL BIOLOGY (2006)
RNAi-mediated gene silencing in non-human primates
TS Zimmermann et al.
NATURE (2006)
Progress towards in vivo use of siRNAs
MA Behlke
MOLECULAR THERAPY (2006)
High doses of siRNAs induce eri-1 and adar-1 gene expression and reduce the efficiency of RNA interference in the mouse
J Hong et al.
BIOCHEMICAL JOURNAL (2005)
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease
K Sall et al.
OPHTHALMOLOGY (2000)